Abstract
The immunogenicity and cytotoxicity associated with early generations of adenoviral vectors provided a strong incentive for the development of helper-dependent adenovirus, a last generation of adenoviral vectors that is devoid of all viral coding sequences. These vectors have shown to mediate longer high-level transgene expression in vivo with reduced toxicity and thus offer enormous potential for human gene therapy. In addition, they possess a considerably larger cloning capacity than conventional adenoviral vectors making the transfer of large cDNAs, multiple transgenes and longer tissuespecific or regulable promoters possible. In this article, we review the progress made with helper-dependent adenoviral vectors. The development and optimization of scalable production processes and strategies for helper removal will be presented. Current chromatography options available for vector purification and the new challenges facing researchers for the separation of empty particles and/or helper viruses will be discussed. Finally, we will describe recent advances made in our understanding of their interaction with the immune system and their potential as gene delivery vehicles in vivo for the treatment of diseases affecting liver, skeletal muscle and brain.
Keywords: Gutless adenoviral vectors, Vector production, Vector purification, Scaleable technologies, Immune response, In vivo gene transfer
Current Gene Therapy
Title: Advances in Helper-Dependent Adenoviral Vector Research
Volume: 8 Issue: 4
Author(s): Maria M. Segura, Raul Alba, Assumpcio Bosch and Miguel Chillon
Affiliation:
Keywords: Gutless adenoviral vectors, Vector production, Vector purification, Scaleable technologies, Immune response, In vivo gene transfer
Abstract: The immunogenicity and cytotoxicity associated with early generations of adenoviral vectors provided a strong incentive for the development of helper-dependent adenovirus, a last generation of adenoviral vectors that is devoid of all viral coding sequences. These vectors have shown to mediate longer high-level transgene expression in vivo with reduced toxicity and thus offer enormous potential for human gene therapy. In addition, they possess a considerably larger cloning capacity than conventional adenoviral vectors making the transfer of large cDNAs, multiple transgenes and longer tissuespecific or regulable promoters possible. In this article, we review the progress made with helper-dependent adenoviral vectors. The development and optimization of scalable production processes and strategies for helper removal will be presented. Current chromatography options available for vector purification and the new challenges facing researchers for the separation of empty particles and/or helper viruses will be discussed. Finally, we will describe recent advances made in our understanding of their interaction with the immune system and their potential as gene delivery vehicles in vivo for the treatment of diseases affecting liver, skeletal muscle and brain.
Export Options
About this article
Cite this article as:
Segura M. Maria, Alba Raul, Bosch Assumpcio and Chillon Miguel, Advances in Helper-Dependent Adenoviral Vector Research, Current Gene Therapy 2008; 8 (4) . https://dx.doi.org/10.2174/156652308785160647
DOI https://dx.doi.org/10.2174/156652308785160647 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advancements in Liposome-Based Strategies for Effective Drug Delivery to the Brain
Current Medicinal Chemistry Editorial (Thematic Issue: Engineered Magnetic Core@Shell Structures)
Current Pharmaceutical Design Growth Inhibition of Human Non-Small Lung Cancer Cells H460 By Green Tea and Ginger Polyphenols
Anti-Cancer Agents in Medicinal Chemistry A Comparative Molecular Field (CoMFA) Studies on Carbonic Anhydrase Inhibitor hCA IX-Tumor-Associated (Hypoxia)
Letters in Drug Design & Discovery How Immune-inflammatory Processes Link CNS and Psychiatric Disorders: Classification and Treatment Implications
CNS & Neurological Disorders - Drug Targets Molecular Imaging to Monitor Repair of Myocardial Infarction Using Genetically Engineered Bone Marrow-Derived Mesenchymal Stem Cells
Current Gene Therapy The Peripheral Benzodiazepine Receptor: A Promising Therapeutic Drug Target
Current Medicinal Chemistry Interpreting the Mechanisms by which Integrins Promote the Differentiation of Mesenchymal Stem Cells and Integrin Application Prospects
Current Stem Cell Research & Therapy Lipid-based Nanocarriers As An Alternative for Oral Delivery of Poorly Water- Soluble Drugs: Peroral and Mucosal Routes
Current Medicinal Chemistry Cadmium-containing Quantum Dots: Current Perspectives on Their Application as Nanomedicine and Toxicity Concerns
Mini-Reviews in Medicinal Chemistry The Synthesis and Use of Boronated Amino Acids for Boron Neutron Capture Therapy
Anti-Cancer Agents in Medicinal Chemistry Animal Models for the Evaluation of Theranostic Radiopharmaceuticals
Current Radiopharmaceuticals Meet Our Associate Editor
Current Molecular Medicine <i>DBX2</i> Promotes Glioblastoma Cell Proliferation by Regulating <i>REST</i> Expression
Current Pharmaceutical Biotechnology Positron Emitting Tracers in Pre-Clinical Drug Development
Current Radiopharmaceuticals Imaging of Hypoxia Using PET and MRI
Current Pharmaceutical Biotechnology Reviewing the Role of Resveratrol as a Natural Modulator of Microglial Activities
Current Pharmaceutical Design PI-3 Kinase-PTEN Signaling Node: An Intercept Point for the Control of Angiogenesis
Current Pharmaceutical Design HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination
Anti-Cancer Agents in Medicinal Chemistry